NLS Pharmaceutics to Participate in Upcoming Investor Conferences
NLS Pharmaceutics to Participate in Upcoming Investor Conferences
ZURICH, SWITZERLAND / ACCESSWIRE / January 11, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, is pleased to announce its participation in the following upcoming conferences:
瑞士苏黎世/ACCESSWIRE/2023年1月11日/亚洲网加利福尼亚州圣何塞10月31日电瑞士临床阶段生物制药公司NLS制药有限公司(纳斯达克市场代码：NLSP，NLSPW)(以下简称“公司”)今天高兴地宣布，它将参加即将召开的下列会议：
- 2023 BIO CEO & Investor Conference
- 2023年BIO首席执行官和投资者大会
Alex Zwyer, NLS' Chief Executive Officer, will present a company update at the 2023 BIO CEO & Investor Conference on March 12-14, 2023, and will be available for one-on-one meetings with conference attendees. Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering system:
NLS首席执行官Alex Zwyer将在2023年3月12日至14日举行的2023年BIO CEO和投资者会议上介绍公司最新情况，并将与与会者进行一对一的会议。那些有兴趣安排会议的人可以通过Bio一对一合作系统来实现：
- 35th Annual Roth Conference
- 第35届Roth年会
Alex Zwyer, NLS' Chief Executive Officer, will participate in and host investor meetings at the 35th Annual Roth Conference on March 12-14, 2023.If you plan on attending the conference, please reach out to your ROTH representative to request a meeting.
NLS首席执行官Alex Zwyer将参加2023年3月12日至14日举行的第35届Roth年会并主持投资者会议。如果您计划参加会议，请联系您的Roth代表请求会面。
About NLS Pharmaceutics Ltd.
关于NLS制药有限公司
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS制药有限公司(纳斯达克代码：NLSP)是一家全球开发期生物制药公司，与世界级合作伙伴和国际公认的科学家网络合作，专注于为患有罕见和复杂的中枢神经系统疾病的患者发现和开发创新疗法，这些患者的医疗需求尚未得到满足。NLS总部设在瑞士，成立于2015年，由一支经验丰富的管理团队领导，该团队在开发和商业化候选产品方面有着良好的记录。欲了解更多信息，请访问。
For additional information:
有关更多信息，请访问：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
Marianne Lambertson(投资者和媒体)
NLS制药有限公司。
+1 239.682.8500
邮箱：ml@nls-pharma.com
SOURCE: NLS Pharmaceutics AG
资料来源：NLS制药公司